Original language | English |
---|---|
Journal | Leukemia |
Volume | 34 |
Issue number | 8 |
Pages (from-to) | 2234-2237 |
Number of pages | 4 |
ISSN | 0887-6924 |
DOIs | |
Publication status | Published - 01.08.2020 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Leukemia, Vol. 34, No. 8, 01.08.2020, p. 2234-2237.
Research output: Journal Articles › Journal articles › Research › peer-review
TY - JOUR
T1 - Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
AU - Rambaldi, Alessandro
AU - Iurlo, Alessandra
AU - Vannucchi, Alessandro M.
AU - Noble, Richard
AU - von Bubnoff, Nikolas
AU - Guarini, Attilio
AU - Martino, Bruno
AU - Pezzutto, Antonio
AU - Carli, Giuseppe
AU - De Muro, Marianna
AU - Luciani, Stefania
AU - McMullin, Mary Frances
AU - Cambier, Nathalie
AU - Marolleau, Jean Pierre
AU - Mesa, Ruben A.
AU - Tibes, Raoul
AU - Pancrazzi, Alessandro
AU - Gesullo, Francesca
AU - Bettica, Paolo
AU - Manzoni, Sara
AU - Di Tollo, Silvia
N1 - Funding Information: Acknowledgements This study was funded by Italfarmaco S.p.A. David Young of Young Medical Communications and Consulting Ltd, a medical writer supported by funding from Italfarmaco S.p.A., provided drafts and editorial assistance to the authors during preparation of this paper. The authors would like to thank the investigators who recruited patients, including Dr Andrzej Hellmann, and the patients at the investigative sites for their support of this study. Funding Information: Conflict of interest AR has received honoraria for consultancy, and travel support from Italfarmaco, Gilead, Amgen, Novartis, Pfizer, Celgene, Sanofi, Astellas and Roche. AI has received speaker honoraria from Novartis, Pfizer and Incyte. AMV has received honoraria for advisory board participation from Novartis, Celgene, Incyte, CTI and Italfarmaco, and for lectures from Novartis, and CTI. N.v.B. received research funding from Novartis. MFM has received honoraria and has attended advisory boards with Novartis, and has received honoraria from Celgene. RAM has received honoraria as a consultant to Novartis, Sierra Oncology, and La Jolla Oncology, and research support from Incyte, Genentech, Celgene, CTI, and Abbvie. RT has advised and received honoraria from Italfarmaco. PB, SM, and SDT are employees of Italfarmaco SpA, the sponsor of the study. RN, AG, BM, AP, GC, MDM, SL, NC, J-PM, APancrazzi, FG have no conflicts to disclose. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/1
Y1 - 2020/8/1
UR - http://www.scopus.com/inward/record.url?scp=85079460133&partnerID=8YFLogxK
U2 - 10.1038/s41375-020-0735-y
DO - 10.1038/s41375-020-0735-y
M3 - Journal articles
C2 - 32047238
AN - SCOPUS:85079460133
SN - 0887-6924
VL - 34
SP - 2234
EP - 2237
JO - Leukemia
JF - Leukemia
IS - 8
ER -